Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib.

ABSTRACT: Liver cancer is highly malignant, has a low sensitivity to chemotherapy, and is associated with poor patient prognosis. The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma (HCC). For over 10 years, before the discovery of lenvatinib, sorafenib was only first-line therapeutic agent available for the treatment of advanced HCC. However, several clinical studies have shown that a considerable proportion liver cancer patients are insensitive to sorafenib. Very few patients actually substantially benefit from treatment with sorafenib, and the overall efficacy of the drug has not been satisfactory; therefore, sorafenib has attracted considerable research attention. This study, which is based on previous studies and reports, review

SUBMITTER: Jiang Z 

PROVIDER: S-EPMC9939808 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature